More tools:Markets·Screener·Research·Chat

Evolus, Inc. Common Stock (EOLS) Financial Statements

Evolus, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG005CX4HL7
XNAS · usd
8.88▼ 0.42 (-4.52%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close9.30
Day's Range8.75 – 9.12
52-Week Range3.86 – 9.31
Volume1.7M
Avg Volume1.1M
Share Statistics
Shares Outstanding
Employees334
ExchangeXNAS
Listed2018-02-08
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Evolus, Inc. Common Stock (EOLS)
What is Evolus, Inc. Common Stock's Market Cap?
Evolus, Inc. Common Stock's Market Cap is $586.5M, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's Enterprise Value?
Evolus, Inc. Common Stock's Enterprise Value is $698.1M, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's Price / Sales?
Evolus, Inc. Common Stock's Price / Sales is 1.9×, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's EV / Revenue?
Evolus, Inc. Common Stock's EV / Revenue is 2.2×, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's EV / EBITDA?
Evolus, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's Revenue (TTM)?
Evolus, Inc. Common Stock's Revenue (TTM) is $316.5M, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's Net Income (TTM)?
Evolus, Inc. Common Stock's Net Income (TTM) is -$34.3M, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's EBITDA?
Evolus, Inc. Common Stock's EBITDA is -$9.8M, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's Diluted EPS (TTM)?
Evolus, Inc. Common Stock's Diluted EPS (TTM) is -0.52, based on as-reported figures from SEC (XBRL) filings.
What is Evolus, Inc. Common Stock's EBITDA Margin?
Evolus, Inc. Common Stock's EBITDA Margin is -3.1%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total net revenues
YoY growth+21.2%+6.7%+14.4%+12.9%
Cost of goods sold
Gross profit
% of revenue68.0%66.9%65.7%66.5%
Operating expenses:
Selling, general and administrative
Research and development
Revaluation of contingent royalty obligation payable to Evolus Founders
Depreciation and amortization
Total operating expenses
% of revenue73.4%76.2%61.0%83.1%
Loss from operations
% of revenue-5.4%-9.4%4.7%-16.7%
Other income (expense):
Interest income
Interest expense
Other income (expense), net
Loss before income taxes
Income tax benefit (expense)
Net loss
% of revenue-9.6%-14.6%0.1%-22.8%
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)